Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma

September 20th 2025

Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

September 20th 2025

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Linvoseltamab Yields Favorable Safety Profile and Antimyeloma Activity in High-Risk Smoldering Myeloma

September 19th 2025

Linvoseltamab monotherapy generated responses and had a favorable safety profile with low rates of high-grade TEAEs in high-risk smoldering myeloma.

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

September 19th 2025

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma

September 19th 2025

The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma

September 19th 2025

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

September 19th 2025

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma

September 19th 2025

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma

September 19th 2025

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Co-Infusion of Anti-GPRC5D/Anti-BCMA Therapies Is Feasible, Yields Durable Responses in R/R Multiple Myeloma

September 19th 2025

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma

September 19th 2025

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Iberdomide/Daratumumab/Dexamethasone Is Effective in Newly Diagnosed Multiple Myeloma

September 18th 2025

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Dr San Miguel on the Association Between MRD-Negative CR and PFS/Safety in Newly Diagnosed Myeloma

September 18th 2025

Jesús San Miguel, MD, PhD, discusses patient-reported outcomes and safety for patients with newly diagnosed multiple myeloma who achieved MRD negativity and a CR or better.

Linvoseltamab Plus Carfilzomib Is Safe, Feasible, and Elicits Durable Responses in R/R Myeloma

September 18th 2025

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma

September 18th 2025

Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.

Daratumumab-Based Regimens Yield Clinical Benefit Irrespective of Frailty Changes in Newly Diagnosed, Transplant-Ineligible Myeloma

September 18th 2025

Post hoc data demonstrated benefit with daratumumab-based regimens in newly diagnosed, transplant-ineligible myeloma, regardless of frailty changes.